We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Alphabet, Amazon, AbbVie, Walmart, and Toyota Motor
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 12, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alphabet Inc. (GOOGL - Free Report) , Amazon.com, Inc. (AMZN - Free Report) , AbbVie Inc. (ABBV - Free Report) , Walmart Inc. (WMT - Free Report) and Toyota Motor Corp. (TM - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Alphabet, Amazon and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc., Amazon.com, Inc., and AbbVie Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Alphabet have outperformed the Zacks Internet - Services industry over the past year (+18.8% vs. +2.8%) on the back of the search giant's leverage to ad spending and strong cloud division. Alphabet's expanding data centers will continue to bolster its presence in the cloud space. Further, major updates in its search segment are enhancing the search results.
The Zacks analyst believes that Google's mobile search is gaining solid momentum. Also, a strong focus on innovation of AI techniques and the home automation space should aid business growth in the long term. Further, its deepening focus on the wearables category remains a tailwind.
The company's growing efforts to gain a foothold in the healthcare industry are other positives. Also, Alphabet's expanding presence in the autonomous driving space is contributing well. However, its growing litigation issues and increasing expenses are concerns.
Amazon shares have gained lagged the broader market over the past year (-10.4% vs +9%) on persistent worries that the company's Covid outperformance was at the expense of future results. There is also the issue of growth stocks in the Fed tightening cycle. These are reasonable issues, but the Zacks analyst sees the company well positioned for the long run given solid Prime momentum and solid positioning in the cloud space (Amazon Web Services or AWS). Further, robust Alexa skills and expanding smart home products portfolio are positives.
The Zacks analyst believes that a strong global presence and solid momentum among the small and medium businesses remain tailwinds. However, growing expenses associated with supply-chain constraints and labor supply shortages remain concerns.
Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+69.1% vs. +38.7%). The Zacks analyst believes that Humira has been performing well in the United States based on strong demand trends. AbbVie has several new drugs in its portfolio, which can drive revenues once Humira loses U.S. exclusivity in 2023. Skyrizi and Rinvoq are going strong. It has an impressive late-stage pipeline with several early/mid-stage candidates that have blockbuster potential.
Allergan's acquisition has diversified AbbVie's revenue base into new therapeutic area. However, there are concerns about long-term sales growth once Humira generics enter the U.S. market. Increasing competition from newer therapies is hurting Imbruvica's sales.
Other noteworthy reports we are featuring today include Walmart Inc. and Toyota Motor Corp..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Alphabet, Amazon, AbbVie, Walmart, and Toyota Motor
For Immediate Release
Chicago, IL – April 12, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alphabet Inc. (GOOGL - Free Report) , Amazon.com, Inc. (AMZN - Free Report) , AbbVie Inc. (ABBV - Free Report) , Walmart Inc. (WMT - Free Report) and Toyota Motor Corp. (TM - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Alphabet, Amazon and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc., Amazon.com, Inc., and AbbVie Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Alphabet have outperformed the Zacks Internet - Services industry over the past year (+18.8% vs. +2.8%) on the back of the search giant's leverage to ad spending and strong cloud division. Alphabet's expanding data centers will continue to bolster its presence in the cloud space. Further, major updates in its search segment are enhancing the search results.
The Zacks analyst believes that Google's mobile search is gaining solid momentum. Also, a strong focus on innovation of AI techniques and the home automation space should aid business growth in the long term. Further, its deepening focus on the wearables category remains a tailwind.
The company's growing efforts to gain a foothold in the healthcare industry are other positives. Also, Alphabet's expanding presence in the autonomous driving space is contributing well. However, its growing litigation issues and increasing expenses are concerns.
(You can read the full research report on Alphabet here >>>)
Amazon shares have gained lagged the broader market over the past year (-10.4% vs +9%) on persistent worries that the company's Covid outperformance was at the expense of future results. There is also the issue of growth stocks in the Fed tightening cycle. These are reasonable issues, but the Zacks analyst sees the company well positioned for the long run given solid Prime momentum and solid positioning in the cloud space (Amazon Web Services or AWS). Further, robust Alexa skills and expanding smart home products portfolio are positives.
The Zacks analyst believes that a strong global presence and solid momentum among the small and medium businesses remain tailwinds. However, growing expenses associated with supply-chain constraints and labor supply shortages remain concerns.
(You can read the full research report on Amazon here >>>)
Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+69.1% vs. +38.7%). The Zacks analyst believes that Humira has been performing well in the United States based on strong demand trends. AbbVie has several new drugs in its portfolio, which can drive revenues once Humira loses U.S. exclusivity in 2023. Skyrizi and Rinvoq are going strong. It has an impressive late-stage pipeline with several early/mid-stage candidates that have blockbuster potential.
Allergan's acquisition has diversified AbbVie's revenue base into new therapeutic area. However, there are concerns about long-term sales growth once Humira generics enter the U.S. market. Increasing competition from newer therapies is hurting Imbruvica's sales.
(You can read the full research report on Abbvie here >>>)
Other noteworthy reports we are featuring today include Walmart Inc. and Toyota Motor Corp..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.